Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 11, 2026

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
08:31

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

Reply: To PMID 22459360

April W Armstrong, Julie Wu

    Journal of the American Academy of Dermatology
    |May 18, 2013
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: May 11, 2026

    Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
    08:31

    Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

    Published on: October 11, 2019

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Concordance Between Patient- and Physician-Reported Improvement With Dupilumab in Atopic Dermatitis.

    The Journal of dermatology·2026
    Same author

    Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis.

    The Journal of dermatological treatment·2026
    Same author

    Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel.

    Journal of drugs in dermatology : JDD·2026
    Same author

    GLP-1RAs and cardiovascular risk reduction in psoriasis: A retrospective cohort study.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2026
    Same author

    Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema.

    Journal of drugs in dermatology : JDD·2026
    Same author

    Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence.

    Journal of drugs in dermatology : JDD·2026
    Same journal

    Real-world experience with extended deucravacitinib-biologic combination therapy in refractory psoriasis and psoriatic arthritis.

    Journal of the American Academy of Dermatology·2026
    Same journal

    Acute-phase Disease and Super-responder Status Predict Reduced Relapse Risk After Ritlecitinib Withdrawal in Alopecia Areata: A Prospective Real-World Study.

    Journal of the American Academy of Dermatology·2026
    Same journal

    Response to Kvist-Hansen et al. 'Baseline monocytes ≥925/μL appear to represent a rare outlier phenotype rather than a generalizable predictor of adalimumab response in hidradenitis suppurativa.'

    Journal of the American Academy of Dermatology·2026
    Same journal

    Navigating Difficult Conversations: Contraceptive Communication with Transgender and Gender Diverse Patients Starting Isotretinoin.

    Journal of the American Academy of Dermatology·2026
    Same journal

    Ultrasound-Guided Hyaluronidase Administration with Remote Expert Guidance for Vascular Adverse Events after Filler Treatment.

    Journal of the American Academy of Dermatology·2026
    Same journal

    Adalimumab Biosimilars and Access Barriers in Dermatology.

    Journal of the American Academy of Dermatology·2026
    See all related articles